Mary Caffrey

The observational study will use information from 3 databases to compare the SGLT2 inhibitor to a competing class of therapy for type 2 diabetes. Early cardiovascular and safety data were presented Monday at the 79th Scientific Sessions of the American Diabetes Association.

Patients with type 2 diabetes (T2D) who had been using insulin an average of 8 years and had mean glycated hemoglobin (A1C) levels of 8.9% were able to bring their levels down 0.9% after 3 months, according to chart review data from 3 European countries.

Findings reported at the 79th Scientific Session of the American Diabetes Association in San Francisco, California, show the type 2 diabetes drug dapagliflozin significantly reduced the risk of renal decline, kidney failure, and renal death.

Results from a study involving adding sitagliptin and increasing doses of metformin for patients who cannot attain glycemic control show that as glycated hemoglobin increases, it becomes harder to reach targets.

Oral semaglutide would be the first non-injectable agent in the GLP-1 receptor agonist class; these drugs produce powerful glycemic control along with weight loss.

More than 5 years after the full implementation of the Affordable Care Act, outcomes data on the effects of Medicaid expansion are starting to emerge.

The essay appears as 9 states have passed laws that are designed to provoke challenges to Roe v Wade before the Supreme Court of the United States.

The authors, from the CDC, say that while the decline in diabetes incidence occurred alongside public health efforts, it's too soon to assume a causal relationship.

The follow-up to the landmark TAILORx trial shows that adding a clinical risk evaluation of the breast cancer tumor may have prognostic value; the authors' recommendations are drawn from other studies.

Lack of awareness of hypoglycemia symptoms can be dangerous, because the person with diabetes can experience a dangerous drop in blood sugar; chronic low blood glucose can result in complications.

The analysis showed the opioid cessation rate at 18 months after surgery was 64% among those who used the pain medication before joint replacement, and 95% among those who did not.

This week, the American Psychiatric Association released results of a public opinion survey on several key mental health issues, including how well employees can access mental health care at work.

A well-known brand of blood glucose meters, lancets, and test strips has tapped Sanvita Medical to develop sensors that integrate with its OneTouch Reveal diabetes management app.

The 175th Annual Meeting of the American Psychiatric Association featured a session on how cultural and ethnic differences could affect reponses to drugs.

Studies presented in posters at the 175th Annual Meeting of the American Psychiatric Association demonstrated that the combination of olanzapine and samidorphan kept weight gain below levels typically seen in commonly used antipsychotics.

The poll by the American Psychiatric Association found that young men were especially reluctant to seek mental health care from their employers, even though most workers, especially young ones, said they felt willing to discuss mental health in the workplace.

The American Journal of Psychiatry published one of the studies that led to approval of one of the most anticipated therapies in years: esketamine for treatment-resistant depression.

The presenter of the study said the results show that children who are in a severe mass trauma need to be closely followed, and clinicians need to screen for trauma as a medical issue.

A discussion with University of California at Berkeley sociologist Arlie Hochschild, PhD, author of the best-seller Strangers in Their Own Land: Anger and Mourning on the American Right, addressed how social psychiatry can help bridge the current political divide.

The 175th Annual Meeting of the American Psychiatric Association, meeting in San Francisco, California, featured research about loneliness among minority women at midlife.

Some people living with type 1 diabetes are unhappy with commercial technology currently avaiable, while others see their choices limited by payer coverage decisions.

Dual inhibitors target both the SGLT1 and SGLT2 proteins in the digestive and renal systems to prevent reuptake of excess glucose.

Cure rates for Hodgkin lymphoma are high, but survivors may live for decades with side effects from chemotherapy. Finding a new treatment target could lead to fewer toxic effects.

Researchers say by targeting a protein that assists KRAS mutations, they have overcome the challeges of resistance to treatment in a mouse model.

As pharmaceutical manufacturers and pharmacy benefit managers point fingers over who is responsible for high drug prices, employers have the opportunity to demand change to business as usual, consultant Chris Robbins of Arxcel says.

Bryan Chiang's concept lets a user take a photo of the eye using a special adapter on the smartphone; the image is then analyzed to predict blood glucose levels.

Proof-of-concept studies suggest the treatment that targets CD47 produces a strong response in patients with diffuse large B-cell lymphoma (DLBCL) with fewer adverse effects than current options.

The use of the circulating tumor DNA workflow demonstrated a proof of concept for this system of guiding treatment in the most common form of ovarian cancer.

Older patients who are improperly diagnosed may not gain access to insulin and delivery and monitoring tools, such as pumps or continuous glucose monitoring.

Radiotherapy after chemotherapy is controversial, as evidenced by the fact that doctors for some patients in the study did not follow the protocol for those assigned to radiotherapy and may have affected the results.